Diagnostic Collaboration, Development, Research and Licensing Deals Analysis Report 2024 with Directory of 1640 Agreements Signed Since 2019
May 07, 2024 06:26 ET
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Diagnostic Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Diagnostic Collaboration and...
QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
May 06, 2024 04:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region
May 06, 2024 01:00 ET
|
Biocartis NV
PRESS RELEASE - 06/05/2024, 07:00 CEST Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region Biocartis (Mechelen,...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, QuidelOrtho, Sharecare, and GoodRx and Encourages Investors to Contact the Firm
May 02, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
April 30, 2024 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
April 30, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
April 29, 2024 04:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, QuidelOrtho, Sharecare, and GoodRx and Encourages Investors to Contact the Firm
April 28, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Using AI to Improve Diagnosis of Rare Genetic Disorders
April 25, 2024 09:19 ET
|
Baylor Genetics
Diagnosing rare Mendelian disorders is a labor-intensive task, even for experienced geneticists. Investigators at Baylor College of Medicine are trying to